Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan W Partin

Showing results (321-330 of 349) with videos related to

Pageof 35
Sort By:
Urology|July 25, 2016
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary CareE David Crawford, Matt T Rosenberg, Alan W Partin, et al.
The Journal of Urology|November 9, 2022
Reply by AuthorsBruce J Trock, Yuezhou Jing, Brent Mabey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkersEmmanuel S Antonarakis, Elisabeth I Heath, Janet R Walczak, et al.
Plos One|February 17, 2021
Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancerClaire Guest, Rob Harris, Karen S Sfanos, et al.
The Journal of Urology|August 25, 2022
Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage RadiotherapyBruce J Trock, Yuezhou Jing, Brent Mabey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Can urinary PCA3 supplement PSA in the early detection of prostate cancer?John T Wei, Ziding Feng, Alan W Partin, et al.
The Journal of Urology|July 25, 2017
Prostate Specific Membrane Antigen Targeted <sup>18</sup>F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center StudyMichael A Gorin, Steven P Rowe, Hiten D Patel, et al.
European Urology|March 24, 2009
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogramFelix K Chun, Alexandre de la Taille, Hendrik van Poppel, et al.
The Journal of Urology|December 3, 2014
The prostate health index selectively identifies clinically significant prostate cancerStacy Loeb, Martin G Sanda, Dennis L Broyles, et al.
European Urology|June 11, 2015
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk MenAshley E Ross, Michael H Johnson, Kasra Yousefi, et al.
Pageof 35

Showing results (321-330 of 349) with videos related to

Sort By:
Pageof 35
Urology|July 25, 2016
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary CareE David Crawford, Matt T Rosenberg, Alan W Partin, et al.
The Journal of Urology|November 9, 2022
Reply by AuthorsBruce J Trock, Yuezhou Jing, Brent Mabey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkersEmmanuel S Antonarakis, Elisabeth I Heath, Janet R Walczak, et al.
Plos One|February 17, 2021
Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancerClaire Guest, Rob Harris, Karen S Sfanos, et al.
The Journal of Urology|August 25, 2022
Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage RadiotherapyBruce J Trock, Yuezhou Jing, Brent Mabey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Can urinary PCA3 supplement PSA in the early detection of prostate cancer?John T Wei, Ziding Feng, Alan W Partin, et al.
The Journal of Urology|July 25, 2017
Prostate Specific Membrane Antigen Targeted <sup>18</sup>F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center StudyMichael A Gorin, Steven P Rowe, Hiten D Patel, et al.
European Urology|March 24, 2009
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogramFelix K Chun, Alexandre de la Taille, Hendrik van Poppel, et al.
The Journal of Urology|December 3, 2014
The prostate health index selectively identifies clinically significant prostate cancerStacy Loeb, Martin G Sanda, Dennis L Broyles, et al.
European Urology|June 11, 2015
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk MenAshley E Ross, Michael H Johnson, Kasra Yousefi, et al.
Pageof 35